000 01344 a2200361 4500
005 20250517085558.0
264 0 _c20161213
008 201612s 0 0 eng d
022 _a1558-5042
024 7 _a10.1016/j.soc.2015.11.010
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLi, Daneng
245 0 0 _aAdjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
_h[electronic resource]
260 _bSurgical oncology clinics of North America
_cApr 2016
300 _a311-26 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAdenocarcinoma
_xdrug therapy
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aChemoradiotherapy, Adjuvant
650 0 4 _aChemotherapy, Adjuvant
650 0 4 _aClinical Trials as Topic
650 0 4 _aDeoxycytidine
_xadministration & dosage
650 0 4 _aErlotinib Hydrochloride
_xadministration & dosage
650 0 4 _aFluorouracil
_xadministration & dosage
650 0 4 _aHumans
650 0 4 _aImmunotherapy
650 0 4 _aNeoadjuvant Therapy
650 0 4 _aPancreatic Neoplasms
_xdrug therapy
650 0 4 _aGemcitabine
700 1 _aO'Reilly, Eileen M
773 0 _tSurgical oncology clinics of North America
_gvol. 25
_gno. 2
_gp. 311-26
856 4 0 _uhttps://doi.org/10.1016/j.soc.2015.11.010
_zAvailable from publisher's website
999 _c25862509
_d25862509